Youngju Kim
M.S./PH.D. INTEGRATED COURSE from Sep 2021
Department of Biomedical Sciences, SNUCM
B.S. Department of biotechnology, CHA University,
Republic of Korea
Research interests
Therapeutic antibody, Fc engineering, Alzheimer's disease, COVID-19
Words
Dream as if you'll live forever. Live as if you'll die today.
E-mail: dudwn9800@gmail.com
Patent
1. 아밀로이드 베타 응집체에 특이적으로 결합하는 항-아밀로이드 베타 항체
(이창한, 김영주, 김혜선, 조은화, 최유리, 박보영, 김동환, 임채영)
10-2024-0202939
2. 항-AXL 항체 및 이를 포함하는 조성물
(이창한, 김영주)
10-2025-0086237
3. 항-MERTK 항체 및 이를 포함하는 조성물
(이창한, 김영주)
10-2025-0086236
Publication
3. Low humoral and cellular immune responses early after breakthrough infection may contribute to
severe COVID-19
Frontiers in Immunology (IF: 5.9)
(Chan Mi Lee, Pyoeng Gyun Choe, Chang Kyung Kang, Eunyoung Lee, Kyoung-Ho Song, Ji Han Bang, Eu Suk.
Kim, Hong Bin Kim, Nam Joong Kim, Hang-Rae Kim, Youngju Kim, Chang-Han Lee, Hyun Mu Shin, Sang-Won.
Park, Wan Beam Park, Myoung-don Oh)
2. Construction and validation of a synthetic phage-displayed nanobody library
Korean Journal of Physiology & Pharmacology (IF:2.0)
(Minju Kim#, Xuelian Bai#, Hyewon Im, Jisoo Yang, Youngju Kim, Minjoo MJ Kim, Yeonji Oh, Yuna Jeon,
Hayoung Kwon, Seunghyun Lee* and Chang-Han Lee*)
# Co-first author, *Co-corresponding author
1. Positivity of anti-SARS-CoV-2 nucleocapsid antibody 3 years post COVID-19
Japanese Journal of Infectious Diseases (IF: 2.2), accepted
(Chang Kyung Kang#, Youngju Kim#, Hyeon Jae Jo, Chan Mi Lee, Nam Joong Kim, Chang-Han Lee, Pyoeng.
Gyun Choe*, Wan Beom Park*, Myoung-don Oh)
# Co-first author, *Co-corresponding author